Mealey's (April 29, 2019, 11:35 AM EDT) -- WASHINGTON, D.C. — In an April 26 decision, the Federal Circuit U.S. Court of Appeals found no error in a final written decision by the Patent Trial and Appeal Board that confirmed the validity of 22 claims of a patented method for reducing the toxic effects of chemotherapy (Neptune Generics LLC, et al. v. Eli Lilly & Company, No. 18-1257, Fed. Cir., 2019 U.S. App. LEXIS 12492)....